Sofosbuvir is a nucleotide analog prodrug that inhibits the NS5B RNA-dependent RNA polymerase of HCV, essential for viral replication . Marketed as Sibowe®, it was China’s first domestic NS5B inhibitor approved on March?18,?2020. This item is designed for preclinical research, including virology assays, drug resistance profiling, and pharmacodynamics.

Product Specifications

Mechanism of Action

Sofosbuvir is metabolized intracellularly into its active triphosphate form, which competitively inhibits HCV NS5B polymerase, causing premature termination of RNA synthesis .

Research Applications

• Viral replication assays targeting NS5B polymerase

• Antiviral resistance and combination therapy models

• Hepatocyte pharmacokinetics and metabolic activation studies

• Preclinical evaluation of novel HCV therapies

Safety & Handling

• For research use only—not for human or veterinary use

• Use standard lab PPE (gloves, coat, goggles)

• Store in sealed packaging away from heat or humidity

• Dispose per institutional biosafety protocols

Core Keywords

Sofosbuvir tablet Sibowe, CAS 1190307-88-0, HCV NS5B inhibitor, hepatitis C antiviral research, NMPA H20203108, domestic sofosbuvir China, antiviral drug research compound

Research Use Disclaimer

This product is exclusively for laboratory and research use. It is not approved for clinical, therapeutic, diagnostic, or veterinary applications. Misuse may result in legal or health consequences. Use only under institutional protocols.